AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA

AlphaQuest LLC lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 402.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,045 shares of the company’s stock after purchasing an additional 18,460 shares during the period. AlphaQuest LLC’s holdings in Moderna were worth $636,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Probity Advisors Inc. increased its stake in Moderna by 2.6% during the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after buying an additional 377 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after buying an additional 392 shares in the last quarter. Blue Sky Capital Consultants Group Inc. increased its stake in Moderna by 3.8% during the 1st quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company’s stock worth $429,000 after buying an additional 556 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in Moderna by 1.4% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company’s stock worth $1,152,000 after buying an additional 562 shares in the last quarter. Finally, Empirical Finance LLC increased its stake in Moderna by 7.3% during the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock worth $261,000 after buying an additional 624 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on MRNA. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. Leerink Partners cut their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research note on Friday, August 22nd. Bank of America cut their price objective on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Finally, Barclays lowered their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus price target of $36.86.

Moderna Stock Performance

Shares of Moderna stock opened at $26.66 on Tuesday. Moderna, Inc. has a one year low of $23.15 and a one year high of $57.69. The company has a market cap of $10.41 billion, a price-to-earnings ratio of -3.54 and a beta of 2.01. The business’s 50 day moving average price is $25.91 and its 200 day moving average price is $27.15.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same period in the prior year, the firm posted ($3.33) earnings per share. The firm’s quarterly revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.